Immune Escape during Breast Tumor Progression.

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immunotherapy with checkpoint inhibitors is a leading cancer treatment strategy.
• Its efficacy in breast cancer is restricted, particularly in triple-negative cases, with unclear long-term response durability.
• Limited understanding of tumor immune evasion and disease heterogeneity hinders progress.

Purpose of the Study:

• To review current knowledge on immune changes during breast tumor progression.
• To emphasize the transition from in situ to invasive carcinoma as a critical immunoediting phase.
• To highlight the need for better understanding of early-stage disease and immunologic drivers.

Main Methods:

• Literature review and synthesis of existing research on breast cancer immunology.
• Focus on the immunoediting process during tumor progression.
• Analysis of immune-related changes from in situ to invasive stages.

Main Results:

• Breast tumor progression involves significant immune evasion mechanisms.
• The transition from ductal carcinoma in situ to invasive carcinoma is a crucial point for immunoediting.
• Heterogeneity in metastatic breast cancer complicates treatment responses.

Conclusions:

• Enhanced understanding of early-stage breast cancer immunology is crucial.
• Identifying immunologic drivers of progression can improve immunotherapy strategies.
• Better patient stratification is needed to optimize immunotherapy outcomes in breast cancer.